Skip to content
Medicines & Healthcare products Regulatory Agency
The National Institute for Biological Standards and Control

Confidence in biological medicines

  • Stay connected
  • Shopping Basket
  • Pay Now
  • Login / Register
  • Home
  • Products
  • Standardisation
  • Control testing
  • Science and research
  • Expert services
  • About us
  • QE2
  • Latest news
  • Worldwide impact of NIBSC
  • Mission and values
  • Careers
  • Quality and governance
  • Staff profiles
  • Contact us
  • Collaborations
  • Suppliers
  • Scientific Advisory Committee
  • Minutes of the Animal Welfare and Ethical Review Body
  • Our use of animals
  • Privacy notice
  • Home  /  
  • About us  /  
  • Latest news  /  
  • NIBSC part of VAC2VAC consortium

NIBSC part of VAC2VAC consortium for assessing the safety and quality of vaccines

NIBSC is part of a public–private consortium of 19 partners tasked with developing an alternative strategy for assessing the safety and quality of human and veterinary vaccines. Funded by the Innovative Medicines Initiative (IMI2), the VAC2VAC project will run for 5 years and brings together experts from the vaccine industry, academia and regulatory authorities.

In addition to providing expert scientific and regulatory advice, NIBSC will lead on the development and evaluation of immunochemical methods for routine batch quality testing of vaccines including those that protect against
diphtheria, tetanus and acellular pertussis.

Read the press release in full.

 
 
 
  • Careers
  • Terms and conditions
  • Accessibility
  • Privacy notice
  • Cookies
  • Sitemap